Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 63975 entries
Sorted by: Best Match Show Resources per page
Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.

International journal of endocrinology

Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K.
PMID: 23097668
Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11.

Aldosterone, a specific mineralocorticoid receptor (MR) agonist and a key player in the development of hypertension, is synthesized as a final product of renin-angiotensin-aldosterone system. Hypertension can be generally treated by negating the effects of angiotensin II through the...

Cite
Ikeda K, Isaka T, Fujioka K, et al. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467doi: 10.1155/2012/519467.
Ikeda, K., Isaka, T., Fujioka, K., Manome, Y., & Tojo, K. (2012). Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. International journal of endocrinology, 2012519467. https://doi.org/10.1155/2012/519467
Ikeda, Keiichi, et al. "Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists." International journal of endocrinology vol. 2012 (2012): 519467. doi: https://doi.org/10.1155/2012/519467
Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11. PMID: 23097668; PMCID: PMC3477571.
Copy Download .nbib Format: NLM
Thyrotoxicosis of Pregnancy.

Journal of clinical & translational endocrinology

Labadzhyan A, Brent GA, Hershman JM, Leung AM.
PMID: 25243108
J Clin Transl Endocrinol. 2014 Dec 01;1(4):140-144. doi: 10.1016/j.jcte.2014.07.008.

Thyrotoxicosis presenting during pregnancy is a common clinical problem and can be challenging to differentiate between physiologic patterns of thyroid dysfunction during gestation and intrinsic hyperthyroidism. This review provides a summary of the differential diagnosis, clinical presentation, diagnostic options,...

Cite
Labadzhyan A, Brent GA, Hershman JM, et al. Thyrotoxicosis of Pregnancy. J Clin Transl Endocrinol. 2014;1(4):140-144doi: 10.1016/j.jcte.2014.07.008.
Labadzhyan, A., Brent, G. A., Hershman, J. M., & Leung, A. M. (2014). Thyrotoxicosis of Pregnancy. Journal of clinical & translational endocrinology, 1(4), 140-144. https://doi.org/10.1016/j.jcte.2014.07.008
Labadzhyan, Artak, et al. "Thyrotoxicosis of Pregnancy." Journal of clinical & translational endocrinology vol. 1,4 (2014): 140-144. doi: https://doi.org/10.1016/j.jcte.2014.07.008
Labadzhyan A, Brent GA, Hershman JM, Leung AM. Thyrotoxicosis of Pregnancy. J Clin Transl Endocrinol. 2014 Dec 01;1(4):140-144. doi: 10.1016/j.jcte.2014.07.008. PMID: 25243108; PMCID: PMC4166486.
Copy Download .nbib Format: NLM
A study of bone mineral density and its determinants in type 1 diabetes mellitus.

Journal of osteoporosis

Joshi A, Varthakavi P, Chadha M, Bhagwat N.
PMID: 23607045
J Osteoporos. 2013;2013:397814. doi: 10.1155/2013/397814. Epub 2013 Mar 31.

Type 1 diabetes mellitus (T1DM) has been inconsistently associated with low bone mineral density (BMD) and increased fracture risk. 86 consecutive T1DM cases and 140 unrelated age and sex matched healthy nondiabetic controls were included in the study. After...

Cite
Joshi A, Varthakavi P, Chadha M, et al. A study of bone mineral density and its determinants in type 1 diabetes mellitus. J Osteoporos. 2013;2013:397814doi: 10.1155/2013/397814.
Joshi, A., Varthakavi, P., Chadha, M., & Bhagwat, N. (2013). A study of bone mineral density and its determinants in type 1 diabetes mellitus. Journal of osteoporosis, 2013397814. https://doi.org/10.1155/2013/397814
Joshi, Ameya, et al. "A study of bone mineral density and its determinants in type 1 diabetes mellitus." Journal of osteoporosis vol. 2013 (2013): 397814. doi: https://doi.org/10.1155/2013/397814
Joshi A, Varthakavi P, Chadha M, Bhagwat N. A study of bone mineral density and its determinants in type 1 diabetes mellitus. J Osteoporos. 2013;2013:397814. doi: 10.1155/2013/397814. Epub 2013 Mar 31. PMID: 23607045; PMCID: PMC3628496.
Copy Download .nbib Format: NLM
Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study.

BMC endocrine disorders

Sigurjonsdottir HA, Gronowitz M, Andersson O, Eggertsen R, Herlitz H, Sakinis A, Wangberg B, Johannsson G.
PMID: 22958674
BMC Endocr Disord. 2012 Sep 08;12:17. doi: 10.1186/1472-6823-12-17.

BACKGROUND: The existence of unilateral adrenal hyperplasia (AH) has been considered a rare cause of primary hyperaldosteronism (PA).METHODS: In a prospective study we screened for PA in a non-selected (NSP) and selected hypertensive population (SP), to define the cause...

Cite
Sigurjonsdottir HA, Gronowitz M, Andersson O, et al. Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study. BMC Endocr Disord. 2012;12:17doi: 10.1186/1472-6823-12-17.
Sigurjonsdottir, H. A., Gronowitz, M., Andersson, O., Eggertsen, R., Herlitz, H., Sakinis, A., Wangberg, B., & Johannsson, G. (2012). Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study. BMC endocrine disorders, 1217. https://doi.org/10.1186/1472-6823-12-17
Sigurjonsdottir, Helga Agusta, et al. "Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study." BMC endocrine disorders vol. 12 (2012): 17. doi: https://doi.org/10.1186/1472-6823-12-17
Sigurjonsdottir HA, Gronowitz M, Andersson O, Eggertsen R, Herlitz H, Sakinis A, Wangberg B, Johannsson G. Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study. BMC Endocr Disord. 2012 Sep 08;12:17. doi: 10.1186/1472-6823-12-17. PMID: 22958674; PMCID: PMC3515501.
Copy Download .nbib Format: NLM
Outcome of endoscopic transsphenoidal surgery in combination with somatostatin analogues in patients with growth hormone producing pituitary adenoma.

Journal of Korean Neurosurgical Society

Zhou T, Wang F, Meng X, Ba J, Wei S, Xu B.
PMID: 25535518
J Korean Neurosurg Soc. 2014 Nov;56(5):405-9. doi: 10.3340/jkns.2014.56.5.405. Epub 2014 Nov 30.

OBJECTIVE: To determine the efficacy of endoscopic surgery in combination with long-acting somatostatin analogues (SSAs) in treating patients with growth hormone (GH)-secreting pituitary tumor.METHODS: We performed retrospective analysis of 133 patients with GH producing pituitary adenoma who underwent pure...

Cite
Zhou T, Wang F, Meng X, et al. Outcome of endoscopic transsphenoidal surgery in combination with somatostatin analogues in patients with growth hormone producing pituitary adenoma. J Korean Neurosurg Soc. 2014;56(5):405-9doi: 10.3340/jkns.2014.56.5.405.
Zhou, T., Wang, F., Meng, X., Ba, J., Wei, S., & Xu, B. (2014). Outcome of endoscopic transsphenoidal surgery in combination with somatostatin analogues in patients with growth hormone producing pituitary adenoma. Journal of Korean Neurosurgical Society, 56(5), 405-9. https://doi.org/10.3340/jkns.2014.56.5.405
Zhou, Tao, et al. "Outcome of endoscopic transsphenoidal surgery in combination with somatostatin analogues in patients with growth hormone producing pituitary adenoma." Journal of Korean Neurosurgical Society vol. 56,5 (2014): 405-9. doi: https://doi.org/10.3340/jkns.2014.56.5.405
Zhou T, Wang F, Meng X, Ba J, Wei S, Xu B. Outcome of endoscopic transsphenoidal surgery in combination with somatostatin analogues in patients with growth hormone producing pituitary adenoma. J Korean Neurosurg Soc. 2014 Nov;56(5):405-9. doi: 10.3340/jkns.2014.56.5.405. Epub 2014 Nov 30. PMID: 25535518; PMCID: PMC4272999.
Copy Download .nbib Format: NLM
Molecular pathways associated with aggressiveness of papillary thyroid cancer.

Current genomics

Benvenga S, Koch CA.
PMID: 24955023
Curr Genomics. 2014 Jun;15(3):162-70. doi: 10.2174/1389202915999140404100958.

The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its aggressiveness. Geno- and phenotyping of aggressive PTC has advanced our understanding of treatment failures and of potential future therapies. Unraveling molecular...

Cite
Benvenga S, Koch CA. Molecular pathways associated with aggressiveness of papillary thyroid cancer. Curr Genomics. 2014;15(3):162-70doi: 10.2174/1389202915999140404100958.
Benvenga, S., & Koch, C. A. (2014). Molecular pathways associated with aggressiveness of papillary thyroid cancer. Current genomics, 15(3), 162-70. https://doi.org/10.2174/1389202915999140404100958
Benvenga, Salvatore, and Koch, Christian A. "Molecular pathways associated with aggressiveness of papillary thyroid cancer." Current genomics vol. 15,3 (2014): 162-70. doi: https://doi.org/10.2174/1389202915999140404100958
Benvenga S, Koch CA. Molecular pathways associated with aggressiveness of papillary thyroid cancer. Curr Genomics. 2014 Jun;15(3):162-70. doi: 10.2174/1389202915999140404100958. PMID: 24955023; PMCID: PMC4064555.
Copy Download .nbib Format: NLM
Personalization of targeted therapy in advanced thyroid cancer.

Current genomics

Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, Antonelli A.
PMID: 24955027
Curr Genomics. 2014 Jun;15(3):190-202. doi: 10.2174/1389202915999140404101902.

Although generally the prognosis of differentiated thyroid carcinoma (DTC) is good, approximately 5% of people are likely to develop metastases which fail to respond to radioactive iodine, and other traditional therapies, exhibiting a more aggressive behavior. Nowadays, therapy is...

Cite
Fallahi P, Ferrari SM, Mazzi V, et al. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014;15(3):190-202doi: 10.2174/1389202915999140404101902.
Fallahi, P., Ferrari, S. M., Mazzi, V., Vita, R., Benvenga, S., & Antonelli, A. (2014). Personalization of targeted therapy in advanced thyroid cancer. Current genomics, 15(3), 190-202. https://doi.org/10.2174/1389202915999140404101902
Fallahi, Poupak, et al. "Personalization of targeted therapy in advanced thyroid cancer." Current genomics vol. 15,3 (2014): 190-202. doi: https://doi.org/10.2174/1389202915999140404101902
Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, Antonelli A. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014 Jun;15(3):190-202. doi: 10.2174/1389202915999140404101902. PMID: 24955027; PMCID: PMC4064559.
Copy Download .nbib Format: NLM
Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes.

Iranian Red Crescent medical journal

Fathi M, Nikzamir AR, Esteghamati A, Nakhjavani M, Yekaninejad MS.
PMID: 25834741
Iran Red Crescent Med J. 2015 Feb 21;17(2):e19469. doi: 10.5812/ircmj.19469. eCollection 2015 Feb.

BACKGROUND: Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) and vascular endothelial growth factor (VEGF) polymorphisms have been shown to associate with diabetic nephropathy (DN).OBJECTIVES: We examined the hypothesis that ACE-D and VEGF-G alleles act synergistically in association with DN, in patients...

Cite
Fathi M, Nikzamir AR, Esteghamati A, et al. Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes. Iran Red Crescent Med J. 2015;17(2):e19469doi: 10.5812/ircmj.19469.
Fathi, M., Nikzamir, A. R., Esteghamati, A., Nakhjavani, M., & Yekaninejad, M. S. (2015). Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes. Iranian Red Crescent medical journal, 17(2), e19469. https://doi.org/10.5812/ircmj.19469
Fathi, Mohammad, et al. "Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes." Iranian Red Crescent medical journal vol. 17,2 (2015): e19469. doi: https://doi.org/10.5812/ircmj.19469
Fathi M, Nikzamir AR, Esteghamati A, Nakhjavani M, Yekaninejad MS. Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes. Iran Red Crescent Med J. 2015 Feb 21;17(2):e19469. doi: 10.5812/ircmj.19469. eCollection 2015 Feb. PMID: 25834741; PMCID: PMC4376980.
Copy Download .nbib Format: NLM
Quality of Life and Sexual Health in the Aging of PCa Survivors.

International journal of endocrinology

Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, Tubaro A, Gravas S, Carini M, Serni S.
PMID: 24744780
Int J Endocrinol. 2014;2014:470592. doi: 10.1155/2014/470592. Epub 2014 Mar 17.

Prostate cancer (PCa) is the most common malignancy in elderly men. The progressive ageing of the world male population will further increase the need for tailored assessment and treatment of PCa patients. The determinant role of androgens and sexual...

Cite
Gacci M, Baldi E, Tamburrino L, et al. Quality of Life and Sexual Health in the Aging of PCa Survivors. Int J Endocrinol. 2014;2014:470592doi: 10.1155/2014/470592.
Gacci, M., Baldi, E., Tamburrino, L., Detti, B., Livi, L., De Nunzio, C., Tubaro, A., Gravas, S., Carini, M., & Serni, S. (2014). Quality of Life and Sexual Health in the Aging of PCa Survivors. International journal of endocrinology, 2014470592. https://doi.org/10.1155/2014/470592
Gacci, Mauro, et al. "Quality of Life and Sexual Health in the Aging of PCa Survivors." International journal of endocrinology vol. 2014 (2014): 470592. doi: https://doi.org/10.1155/2014/470592
Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, Tubaro A, Gravas S, Carini M, Serni S. Quality of Life and Sexual Health in the Aging of PCa Survivors. Int J Endocrinol. 2014;2014:470592. doi: 10.1155/2014/470592. Epub 2014 Mar 17. PMID: 24744780; PMCID: PMC3976934.
Copy Download .nbib Format: NLM
Mini puberty and its interpretation.

Turk pediatri arsivi

Kurtoğlu S, Baştuğ O.
PMID: 26078661
Turk Pediatri Ars. 2014 Sep 01;49(3):186-91. doi: 10.5152/tpa.2014.2038. eCollection 2014 Sep.

Gonadotropins which are high in the middle of the fetal life are measured to be considerably low in the cord blood and estrogen is found to be high in the cord blood. Gonodotropins are supressed by estrogen. After delivery,...

Cite
Kurtoğlu S, Baştuğ O. Mini puberty and its interpretation. Turk Pediatri Ars. 2014;49(3):186-91doi: 10.5152/tpa.2014.2038.
Kurtoğlu, S., & Baştuğ, O. (2014). Mini puberty and its interpretation. Turk pediatri arsivi, 49(3), 186-91. https://doi.org/10.5152/tpa.2014.2038
Kurtoğlu, Selim, and Baştuğ, Osman. "Mini puberty and its interpretation." Turk pediatri arsivi vol. 49,3 (2014): 186-91. doi: https://doi.org/10.5152/tpa.2014.2038
Kurtoğlu S, Baştuğ O. Mini puberty and its interpretation. Turk Pediatri Ars. 2014 Sep 01;49(3):186-91. doi: 10.5152/tpa.2014.2038. eCollection 2014 Sep. PMID: 26078661; PMCID: PMC4462291.
Copy Download .nbib Format: NLM
Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study.

Patient preference and adherence

Yavuz DG, Bilen H, Sancak S, Garip T, Hekimsoy Z, Sahin I, Yilmaz M, Aydin H, Atmaca A, Sert M, Karakaya P, Arpaci D, Oguz A, Guvener N.
PMID: 27274207
Patient Prefer Adherence. 2016 May 17;10:851-61. doi: 10.2147/PPA.S100626. eCollection 2016.

OBJECTIVE: The objective of this study is to evaluate the impact of sequential telephonic interviews on treatment persistence and daily adherence to insulin injections among insulin-naïve type 2 diabetes patients initiated on different insulin regimens in a 3-month period.METHODS:...

Cite
Yavuz DG, Bilen H, Sancak S, et al. Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study. Patient Prefer Adherence. 2016;10:851-61doi: 10.2147/PPA.S100626.
Yavuz, D. G., Bilen, H., Sancak, S., Garip, T., Hekimsoy, Z., Sahin, I., Yilmaz, M., Aydin, H., Atmaca, A., Sert, M., Karakaya, P., Arpaci, D., Oguz, A., & Guvener, N. (2016). Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study. Patient preference and adherence, 10851-61. https://doi.org/10.2147/PPA.S100626
Yavuz, Dilek Gogas, et al. "Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study." Patient preference and adherence vol. 10 (2016): 851-61. doi: https://doi.org/10.2147/PPA.S100626
Yavuz DG, Bilen H, Sancak S, Garip T, Hekimsoy Z, Sahin I, Yilmaz M, Aydin H, Atmaca A, Sert M, Karakaya P, Arpaci D, Oguz A, Guvener N. Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study. Patient Prefer Adherence. 2016 May 17;10:851-61. doi: 10.2147/PPA.S100626. eCollection 2016. PMID: 27274207; PMCID: PMC4876103.
Copy Download .nbib Format: NLM
Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope.

Acta medica Iranica

Aghaei Meybodi HR, Hasanzad M, Larijani B.
PMID: 28282717
Acta Med Iran. 2017 Mar;55(3):166-174.

Type 2 diabetes mellitus (T2DM) is recognized as a public health problem and increasingly prevalent illness. Key elements of the guideline for diabetes care are based on evidence-based medicine approach and apply for population, not individuals. However, individualized care...

Cite
Aghaei Meybodi HR, Hasanzad M, Larijani B. Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope. Acta Med Iran. 2017;55(3):166-174
Aghaei Meybodi, H. R., Hasanzad, M., & Larijani, B. (2017). Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope. Acta medica Iranica, 55(3), 166-174.
Aghaei Meybodi, Hamid Reza, et al. "Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope." Acta medica Iranica vol. 55,3 (2017): 166-174.
Aghaei Meybodi HR, Hasanzad M, Larijani B. Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope. Acta Med Iran. 2017 Mar;55(3):166-174. PMID: 28282717.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 63975 entries